Cancer immunotherapy employing an innovative strategy to enhance CD4T cell help in the tumor microenvironment

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Song, Liwen ^a,b,c,d   Yang, Ming Chieh ^e   Knoff, Jayne ^d   Wu, T C ^d   Hung, Chien Fu ^d   Van Hall, Thorbald ^f  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLYSYLPHENYLALANYLVALYLALANYLALANYLTRYPTOPHYLTHREONYLLEUCYLLYSYLALANYLALANINE; CISPLATIN; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; PROTEIN E7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CPG-OLIGONUCLEOTIDE; MALARIA VACCINE; OLIGODEOXYRIBONUCLEOTIDE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PADRE 45;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOMODULATION; LYMPHOCYTOPOIESIS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; DENDRITIC CELL; DRUG EFFECTS; FLOW CYTOMETRY; HELPER CELL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CISPLATIN; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LUNG NEOPLASMS; MALARIA VACCINES; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; PAPILLOMAVIRUS E7 PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84919800808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115711     Document Type: Article

References (26)

1. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, et al. (2013) Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 73: 2493-2504.
2. Wu CY, Yang LH, Yang HY, Knoff J, Peng S, et al. (2014) Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors. Clin Cancer Res 20: 644-657.
3. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, et al. (1994) Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751-761.
4. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, et al. (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918.
5. Hung CF, Tsai YC, He L, Wu TC (2007) DNA vaccines encoding Ii-PADRE generates potent PADREspecific CD4+T-cell immune responses and enhances vaccine potency. Mol Ther 15: 1211-1219.
6. Wu CY, Monie A, Pang X, Hung CF, Wu TC (2010) Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+T help and dendritic cell activation. J Biomed Sci 17: 88.
7. Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, et al. (2011) Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 18: 304-312.
8. Kuchtey J, Chefalo PJ, Gray RC, Ramachandra L, Harding CV (2005) Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. J Immunol 175: 2244-2251.
9. Gray RC, Kuchtey J, Harding CV (2007) CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J Leukoc Biol 81: 1075-1085.
10. Carpentier AF, Chen L, Maltonti F, Delattre JY (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59: 5429-5432.
11. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, et al. (2005) Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116: 992-997.
12. Lee S, Yagita H, Sayers TJ, Celis E (2010) Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immunother 59: 1073-1081.
13. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, et al. (2011) CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17: 1765-1775.
14. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
15. Kim D, Monie A, He L, Tsai YC, Hung CF, et al. (2008) Role of IL-2 secreted by PADRE-specific CD4?+ T cells in enhancing E7-specific CD8+T-cell immune responses. Gene Ther 15: 677-687.
16. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, et al. (2013) Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 62: 171-182.
17. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, et al. (2011) Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117: 5381-5390.
18. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
19. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
20. Kang TH, Knoff J, Yang B, Tsai YC, He L, et al. (2013) Control of spontaneous ovarian tumors by CD8?+ T cells through NKG2D-targeted delivery of antigenic peptide. Cell Biosci 3: 48.
21. Kang TH, Ma B, Wang C, Wu TC, Hung CF (2013) Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+?) T cell-mediated killing. Mol Ther 21: 542-553.
22. La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, et al. (2012) Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205: 1294-1304.
23. Shirota H, Klinman DM (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 13: 299-312.
24. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, et al. (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29: 558-568.
25. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98: 9237-9242.
26. Chuang TH, Lai CY, Tseng PH, Yuan CJ, Hsu LC (2014) Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses. PLoS One 9: e108808.